Strategic Alliances, Partnerships & Collaborations Analysis – March 2018

While M&A activity in the wider healthcare industry is heating up deal making in the diagnostics space remains relatively light, not so much in terms of volume but in size, at least compared to the same period in 2017. Still, the diagnostic industry remains strategically active, particularly in forging new alliances and collaborations. Here is an overview of what happened from late March to mid-April.

Key alliances during the period paired leading diagnostic providers with major pharmaceuticals and biopharm companies, including:

  • A pair of deals involving Illumina, one with Bristol-Myers Squibb aimed at developing new companion diagnostics tests for use with drugs in the BMS pipeline, and another with Loxo Oncology for creating sequencing-based pan-cancer diagnostics for Loxo’s targeted oncology drugs;
  • PATH and Mologic’s collaboration to develop and commercialize a rapid diagnostic test for treating Plasmodium vivax malaria; and
  • Personal Genome Diagnostics’s agreement to work with Five Prime Therapeutics to develop a blood-based companion assay for use with the bemarituzumab investigation drug.

Quest Diagnostics was involved in what may have been the most notable deal of the period, at least in terms of the size of the participants, by joining a new alliance with Humana, UnitedHealthcare, Multiplan et al. launching a pilot program aimed at using blockchain technology to promote data sharing leading to, hopefully, watershed improvements in data quality and cost savings across the wider healthcare industry.

Close

EMAIL ADDRESS


PASSWORD
EMAIL ADDRESS

FIRST NAME

LAST NAME

TITLE

COMPANY

CITY / STATE

Try Premium Membership

(-0000g2)